Increased prevalence of the pfdhfr/phdhps quintuple mutant and rapid emergence of pfdhps resistance mutations at codons 581 and 613 in Kisumu, Kenya by Spalding, Maroya D et al.
RESEARCH Open Access
Increased prevalence of the pfdhfr/phdhps quintuple
mutant and rapid emergence of pfdhps resistance
mutations at codons 581 and 613 in Kisumu, Kenya
Maroya D Spalding
1,4, Fredrick L Eyase
2, Hoseah M Akala
2, Sheryl A Bedno
3, Sean T Prigge
4, Rodney L Coldren
3,
William J Moss
1,4, Norman C Waters
5*
Abstract
Background: Anti-malarial drug resistance in Kenya prompted two drug policy changes within a decade:
sulphadoxine-pyrimethamine (SP) replaced chloroquine (CQ) as the first-line anti-malarial in 1998 and artemether-
lumefantrine (AL) replaced SP in 2004. Two cross-sectional studies were conducted to monitor changes in the
prevalence of molecular markers of drug resistance over the period in which SP was used as the first-line anti-
malarial. The baseline study was carried out from 1999-2000, shortly after implementation of SP, and the follow-up
study occurred from 2003-2005, during the transition to AL.
Materials and methods: Blood was collected from malaria smear-positive, symptomatic patients presenting to
outpatient centers in Kisumu, Kenya, during the baseline and follow-up studies. Isolates were genotyped at codons
associated with SP and CQ resistance. In vitro IC50 values for antifolates and quinolones were determined for
isolates from the follow-up study.
Results: The prevalence of isolates containing the pfdhfr N51I/C59R/S108N/pfdhps A437G/K540E quintuple mutant
associated with SP-resistance rose from 21% in the baseline study to 53% in the follow-up study (p < 0.001).
Isolates containing the pfdhfr I164L mutation were absent from both studies. The pfdhps mutations A581G and
A613S/T were absent from the baseline study but were present in 85% and 61%, respectively, of isolates from the
follow-up study. At follow-up, parasites with mutations at five pfdhps codons, 436, 437, 540, 581, and 613,
accounted for 39% of isolates. The CQ resistance-associated mutations pfcrt K76T and pfmdr1 N86Y rose from 82%
to 97% (p = 0.001) and 44% to 76% (p < 0.001), respectively, from baseline to follow-up.
Conclusions: During the period in which SP was the first-line anti-malarial in Kenya, highly SP-resistant parasites
emerged, including isolates harboring pfdhps mutations not previously observed there. SP continues to be widely
used in Kenya; however, given the highly resistant genotypes observed in this study, its use as a first-line anti-
malarial should be discouraged, particularly for populations without acquired immunity to malaria. The increase in
the pfcrt K76T prevalence, despite efforts to reduce CQ use, suggests that either these efforts are not adequate to
alleviate CQ pressure in Kisumu, or that drug pressure is derived from another source, such as the second-line anti-
malarial amodiaquine.
Background
In Kenya, a sub-Saharan African nation of 34.7 million
people, approximately 70% of the population is at risk for
malaria infection, and malaria accounts for approximately
20% of admissions to health facilities and 30-50% of
outpatient clinic visits [1]. Effective treatment of malaria in
Kenya has been hampered by high levels of drug resis-
tance, both to chloroquine (CQ), which was the first-line
anti-malarial for uncomplicated malaria in Kenya until
1998 [2], and to its replacement, sulphadoxine-pyrimetha-
mine (SP). Widespread treatment failures were observed
within five years of implementing SP as the first-line anti-
malarial, and in 2004 the recommended treatment for
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combination therapy (ACT), artemether-lumefantrine
(AL) [3]. More than two years elapsed before the training
of health care workers and distribution of AL were com-
pleted in 2006 [3]. Although no longer the official first-
line anti-malarial, SP remains available and is frequently
used in the private sector [4]. It also plays an important
role in the prevention of malaria in pregnancy when used
for intermittent presumptive treatment of malaria in preg-
nant women (IPTp) [5] and has been included in several
trials of intermittent presumptive treatment in infants
(IPTi) [6-11].
The efficacy of SP depends on the inhibition of two
parasite enzymes necessary for the synthesis and recy-
cling of folate: dihydrofolate reductase (DHFR), the tar-
get of pyrimethamine, and dihydropteroate synthase
(DHPS), the target of sulphadoxine. The key event in
the development of pyrimethamine resistance is a muta-
tion at codon 108 that changes serine to asparagine,
resulting in partial pyrimethamine resistance. Further
mutation at codons 51 (N51I) and/or 59 (C59R)
increases the severity of pyrimethamine resistance
[12,13]. An additional mutation, I164L, is associated
with high-level SP resistance and has been found in the
presence of triple mutant pfdhfr in South American and
Asian isolates [14,15]. This mutation appears to be rare
in Africa [16], but has been detected at low prevalence
in isolates from Kisumu and Western Kenya [17-19]. In
the background of double or triple mutant pfdhfr, muta-
tions that enhance resistance to antifolates arise in the
pfdhps gene. Five mutations in pfdhps (S436A/F, A437G,
K540E, A581G, and A613S/T) have been implicated in
sulphadoxine resistance [20,21]. In vivo,t h epfdhps dou-
ble mutant A437G/K540E is associated with clinical SP
failure in Africa [13]. Mutations at codons 581 and 613
h a v eb e g u nt oe m e r g ei nA f r i c ai nt h eb a c k g r o u n do f
the A437G mutation [22,23]. These mutations are wide-
spread in South America and South East Asia, and are
associated with high-level SP resistance [15,24].
Together, the pfdhps double mutant A437G/K540E and
the pfdhfr triple mutant S108N/N51I/C59R form the
pfdhfr/pfdhps quintuple mutant, which is associated
with SP treatment failure [13].
Chloroquine resistance is associated with mutations in
two transporters, the chloroquine resistance transporter
(PfCRT) and the transmembrane glycoprotein Pgh1, a
homolog of the mammalian multidrug resistance transpor-
ter encoded by the gene pfmdr1.T h epfcrt mutation K76T
is sufficient for CQ resistance [25]. The pfmdr1 mutation
N86Y is linked with CQ resistance and mefloquine sensi-
tivity [26,27]. In contrast, quinine and mefloquine resis-
tance are associated with parasites that are wild-type at
codon 86, but have increased pfmdr1 copy number [26].
Among other common pfmdr1 polymorphisms, the single
mutation N1042D and the allele combination S1034C/
N1042D/D1286Y are associated with increased in vitro
resistance to quinine and increased susceptibility to meflo-
quine and artemisinin [28]. In vivo, treatment with AL
selects for parasites that are wild-type at codons 86 and
1246 and mutant at codon 184 [29,30]. In Africa, where
CQ has exerted the most drug pressure on these alleles,
the pfcrt K76T haplotype and single copy pfmdr1 with the
N86Y haplotype predominate. While both markers are
associated with CQ resistance, pfcrt K76T is more strongly
associated with in vivo CQ resistance than either pfmdr1
N86Y or both markers together [31]. Research in Malawi
has shown that fitness costs imparted by the K76T muta-
tion result in the return of CQ sensitivity in the absence of
CQ pressure. In 1993, CQ was replaced as the first-line
anti-malarial in Malawi. By 2001, the K76T mutation had
completely disappeared, and in 2006, CQ was demon-
strated to again be effective in vivo [32,33].
In 1999, shortly after SP became the first-line anti-
malarial in Kenya, the U.S. Army initiated a study of the
prevalence of molecular markers of CQ and SP resis-
tance in Kisumu, Kenya, a malaria endemic area near
Lake Victoria. To evaluate changes in molecular markers
of SP and CQ resistance in the presence of continued
SP selection pressure, and presumably decreased CQ
selection pressure, a follow-up study was conducted
from 2003-2005. During this time period, the national
first-line anti-malarial policy changed from SP to AL
due to widespread SP treatment failures, although AL
was not fully implemented until after completion of the
follow-up study [3]. Here, changes in the prevalence of
drug resistance-associated pfdhfr, pfdhps, pfcrt,a n d
pfmdr1 haplotypes in the malaria-endemic area of
Kisumu, Kenya are compared between the baseline and
follow-up studies.
Methods
Study site and Plasmodium falciparum patient isolates
The goal of this study was to compare the prevalence of
molecular markers of drug resistance between the per-
iod directly following adoption of SP as the first-line
anti-malarial in 1998 and approximately five years later.
A baseline study of resistance markers was conducted
from 1999-2000 and was reported previously [34]. The
findings of a second study conducted from August 2003
through July 2005 are described here and compared to
the baseline study results. During both study periods,
P. falciparum isolates were collected from persons in
Kisumu, Kenya, a city located on the shore of Lake Vic-
toria in a region where malaria is holoendemic. Patients
of all ages who presented at the outpatient clinics of
New Nyanza Provincial Hospital, Kisumu, Kenya, tested
positive for malaria by thick smear, and who had not
taken anti-malarial drugs within 24 hours were eligible.
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their parents or guardians. Venous blood for parasite
genotyping and in vitro drug testing was collected from
study subjects prior to anti-malarial treatment. The stu-
dies and protocols were approved by the Institutional
Review Boards at the Walter Reed Army Institute of
Research (WRAIR) and the Kenya Medical Research
Institute (KEMRI).
Genotyping
Blood spots from venous blood collected prior to treat-
ment were dried on filter paper and DNA was isolated
by Chelex extraction. To control for variation between
the studies, genotype analyses for the baseline and fol-
low-up studies were conducted under identical labora-
tory conditions by the same personnel, and laboratory
strains were included as controls. Parasite genotypes at
pfdhfr codons 51, 59, 108 (detection of S108N only),
and 164, pfdhps codons 436, 437, 540, 581, and 613, and
pfcrt codon 76 were determined by mutation-specific
nested PCR. The full-length pfdhfr and pfdhps genes
were amplified in a primary PCR reaction according to
the methods of Duraisingh [35] and Wang [36], respec-
tively. Allele specific PCR analyses were performed
according to published methods [13]. The genotype of
pfcrt codon 76 was determined by nested PCR according
to the methods described by Djimde and colleagues [31].
The genotypes of pfmdr1 codons 86, 184, 1034, 1042,
and 1246 were analysed by PCR-RFLP [31]. Genotypes
were initially classified as wild-type, mutant, or mixed
wild-type and mutant. Isolates were classified as mixed
genotype when strong bands of similar intensity were
detected for both the wild-type and mutant genotypes.
To determine changes in the mutation prevalence at
each locus, isolates were grouped as wild-type (pure
wild-type only) or mutant (pure and mixed mutant). For
each codon, isolates missing data for that codon were
excluded from the mutation prevalence analysis.
pfdhfr/pfdhps haplotype analysis
T h ep r e v a l e n c eo ft h epfdhfr triple mutant allele N51I/
C59R/S108N, the pfdhps double mutant allele A437G/
K540E, and the pfdhfr/pfdhps quintuple mutant were
determined using a modification of the method
described by Kublin and colleagues [13]. This method is
particularly useful for mixed genotype isolates, such as
those observed here. In these isolates, it is difficult to
ascertain haplotype because the observed haplotype is a
combination of the haplotypes of all the parasite lines in
the infection; the method of Kublin and co-workers
accounts for this when classifying haplotypes [13].
Pfdhfr and pfdhps haplotypes were first classified as
wild-type, single mutant, double mutant (mixed or
pure), or, in the case of pfdhfr, triple mutant (mixed or
pure) (Additional file 1). These haplotypes were then
used to determine the pfdhfr/pfdhps haplotype (Addi-
tional file 2). Although in the published method muta-
tions at codons 51 or 59 were always accompanied by
mutant codon 108, several of the Kisumu isolates had
mutations at codons 51 and/or 59 but not 108. Thus, in
these samples, mutation at codon 108 could not be con-
sidered a prerequisite for further pfdhfr mutations, and
the method was modified to classify isolates with mixed
mutations at two pfdhfr loci as single mutant (Addi-
tional file 1). The published method was further modi-
fied by creating a double mutant mixed pfdhps category
to account for the high number of mixed haplotypes in
the samples (Additional file 1).
Due to the high prevalence of pfdhps mutations at
codons 436, 581, and 613 in the follow-up study,
expanded pfdhps haplotypes that included these codons
were constructed. Using the pfdhps A437G/K540E hap-
lotypes (Additional file 1), it was determined whether
isolates that were wild-type, single mutant, or double
mutant at codons 437 and 540 also carried mutations
(mixed and pure mutant combined) at codons 436, 581,
and 613. Isolates for which data were missing for any of
pfdhfr codons 51, 59, or 108 or pfdhps codons 436, 437,
540, 581, and 613 were excluded from all haplotype
analyses.
pfcrt K76T allele frequency estimation
The frequency of the K76T allele in the baseline and
follow-up studies was estimated using the formulas
described by Hill and Babiker, assuming a conditional
Poisson distribution for the number of clones [37].
In vitro drug susceptibility assays
Red blood cells from venous blood samples taken from
smear positive patients were resuspended in folate-free
RPMI (Gibco) supplemented with 10% human serum
and buffered with HEPES and NaHCO3. The culture
suspension was added to 96-well plates containing serial
dilutions of the anti-malarial drugs sulphadoxine, dap-
sone, pyrimethamine, chlorcycloguanil, proguanil, chlor-
oquine, mefloquine, quinine, and amodiaquine. The
reference strains D2 and W6 were included as controls.
Inhibition of parasite growth was assessed by
3H-hypox-
anthine uptake as previously described [38]. The in vitro
IC50 cutoff values used to classify parasites as drug sen-
sitive or resistant were based on published values deter-
mined by the correlation of in vitro IC50 values with in
vivo treatment failure (for CQ) and by the statistical
definition of resistance as an IC50 value greater than two
standard deviations above the mean IC50 of sensitive
parasites (all other drugs). IC50 values considered discri-
minative for resistance were 100 nM (32 ng/ml) for CQ
[39]; 800 nM (259.5 ng/ml) for quinine, with 500 nM
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susceptibility [40]; 30 nM (11.4 ng/ml) for mefloquine;
80 nM (28.5 ng/ml) for amodiaquine [41]; 2 μM
(497.4 ng/ml) for pyrimethamine with intermediate levels
of susceptibility denoted by IC50 values between 500 nM
(124.5 ng/ml) and 2 μM [42]; 32 μM( 1 0μg/ml) for
sulphadoxine [43]; and 12 μM for dapsone (3 μg/ml) [44].
Statistical analysis
Changes in prevalence by study period were analysed by
Fischer’s exact test if one or more cells contained five or
fewer samples, and by the c
2 test for all other analyses.
For all analyses, statistical significance was determined
at the p < 0.05 level. Statistical analyses were performed
with Stata Statistical Software: Release 9.0 (StataCorp,
College Station, TX).
Results
Mutations at four codons in pfdhfr and at five codons in
pfdhps were successfully analysed for 38 to 40 out of 40
total samples from the baseline study (1999-2000) and
220 to 243 out of 250 total samples from the follow-up
study (2003-2005). The prevalence of mutant haplotypes
(mixed and pure mutant) at each locus was compared
between the study periods. In the baseline study [34],
the prevalence of patient isolates containing the pfdhfr
mutations N51I and C59R was high, totaling 97.5% and
100%, respectively, while the prevalence of the mutation
S108N was slightly lower at 87.5%. In the follow-up
study, the mutation prevalence at codons 51 and 59 was
99.6% and 97.0%, respectively, and did not change sig-
nificantly from the baseline study (p = 0.14 and p =
0.28, respectively) (Figure 1A). The prevalence of the
S108N mutation increased significantly to 99.5% (p <
0.001). Thus, after approximately five years of SP use in
Kisumu, over 95% of symptomatic patients had parasites
with mutations at pfdhfr codons 51, 59, and 108 in
either mixed or pure form. The highly drug resistant
mutation I164L was not detected in either study period.
The mutations A437G and K540E are the pfdhps
mutations most strongly associated with SP treatment
failure in Africa [13]. The pfdhps mutations S436A,
A581G, and A613S/T combined with A437G increase
the IC50 of sulfa drugs in in vitro culture relative to
A437G alone [20,21], although their role in in vivo SP
failure is not well understood. The prevalence of A437G
and K540E increased from 37.5% to 98.8% (p < 0.001)
and from 57.5% to 96.3% (p < 0.001), respectively,
between the baseline and follow-up study periods (Fig-
ure 1B). The prevalence of S436A/F increased from
23.7% to 68.6% between the study periods (p < 0.001),
following the trend of increasing mutation prevalence
observed for codons 437 and 540 (Figure 1B). The
mutations A581G and A613S/T were not detected in
the initial study period; however, these mutations were
present in 85.1% (p < 0.001) and 60.7% (p < 0.001) of
isolates from the second study period, respectively.
Changes in prevalence were also analysed for the three
pfdhfr and pfdhps haplotypes that have been associated
with clinical failure of SP: triple mutant pfdhfr N51I/
C59R/S108N, double mutant pfdhps A437G/K540E, and
the pfdhfr/pfdhps quintuple mutant formed from these
combined haplotypes. Haplotype analyses were per-
formed on 38 of the 40 isolates from the baseline study
and 200 of the 250 isolates from the follow-up study
that had complete genotype data for pfdhfr codons 51,
59, and 108 and pfdhps c o d o n s4 3 6 ,4 3 7 ,5 4 0 ,5 8 1 ,a n d
613. The prevalence of the pfdhfr triple mutant (mixed
and pure mutant combined) decreased from 81.5% in
the baseline study to 68.0% in the follow-up study, with
a coincident rise in the prevalence of pfdhfr double
mutants from 18.4% to 32.0% (p < 0.001) (Figure 2A).
The percentage of isolates containing the pfdhps double
mutant (mixed and pure combined) increased from
23.7% in the baseline study period to 76.5% in the fol-
low-up period (p < 0.001) (Figure 2B). The prevalence
of parasites wild-type at pfdhps codons 437 and 540
decreased between the two study periods from 31.6% to
0.5%. The pfdhfr/pfdhps quintuple mutant, in either
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Page 4 of 10mixed or pure form, is the most clinically relevant mole-
cular marker for SP resistance. The prevalence of mixed
and pure quintuple mutant parasites increased from
21.1% to 53.5% in the three to five year interval between
studies (p < 0.001) (Figure 2C).
Based on the high prevalence of pfdhps mutations at
codons other than 437 and 540 in the follow-up study,
pfdhps genotypes were constructed based on whether
isolates that were wild-type, single, or double mutant at
codons 437 and 540 had additional mutations at codons
436, 581, and 613. In the baseline study, isolates that
were wild-type at codons 436, 581, and 613 and single
or double mutant at codons 437 and 540 accounted for
34.2% and 15.8% of isolates, respectively. Only 7.9% of
isolates that were A437G/K540E double mutant also
had an additional mutation (Figure 3A). In the follow-
up study, isolates that were A437G/K540E double
mutant with additional mutations in pfdhps predomi-
nated, such that 14.5% of isolates had one additional
mutation, 17.5% had two additional mutations, and
38.5% had three additional mutations (Figure 3A). Only
5.5% contained the A437G/K540E double mutant with-
out additional mutations in pfdhps. An additional 17.5%
of isolates were single mutant with respect to codons
437 and 540 and carried mutations at codons 436, 581,
and 613. In the baseline study, A437G/K540E double
mutant isolates were found with one additional muta-
tion, S436A/F; however, in the follow-up study, the
majority of isolates with one additional mutation carried
A581G (Figure 3B). Among double mutant isolates with
50
1999-2000
2003 2005
A
20
30
40
2003-2005
P
r
e
v
a
l
e
n
c
e
 
(
%
)
P
r
e
v
a
l
e
n
c
e
 
(
%
)
W 1 2M 2P 3M 3P
0
10
30
40
50
1999-2000
2003-2005
n
c
e
 
(
%
)
B
e
n
c
e
 
(
%
)
e
n
c
e
 
(
%
)
W 1 2M 2P
0
10
20
P
r
e
v
a
l
e
n
P
r
e
v
a
l
e
P
r
e
v
a
l
e
40
50
1999-2000
2003-2005
C
)
10
20
30
P
r
e
v
a
l
e
n
c
e
 
(
%
)
P
r
e
v
a
l
e
n
c
e
 
(
%
W123 4 5M 5P
0
Figure 2 Prevalence of (A) pfdhfr,( B )pfdhps,a n d( C )pfdhfr/
pfdhps haplotypes with respect to pfdhfr codons 51, 59, and
108 and pfdhps codons 437 and 540 in patient isolates from
the baseline and follow-up studies. Genotypes are wild-type (W),
single (1), double (2), triple (3), quadruple (4), and quintuple (5)
mutant, with mixed genotypes denoted by M and pure genotypes
by P.
A
e
v
a
l
e
n
c
e
 
(
%
)
1999-2000
2003-2005
pfdhps genotype
P
r
e
BC
S436A/F
A613S/T
A581G
S436A/F+A613S/T
A581G+A613S/T
S436A/F+A581G
P
r
e
v
a
l
e
n
c
e
 
(
%
)
P
r
e
v
a
l
e
n
c
e
 
(
%
)
study period
pfdhps genotype DM + 1
2 1 2
DM + 2
Figure 3 Prevalence of pfdhps haplotypes with respect to
codons 436, 437, 540, 581, and 613. (A) Prevalence of pfdhps
haplotypes that are wild-type at all five codons (WT), single or
double mutant with respect to A437G and K540E (SM or DM), single
mutant with three additional mutations at codons 436, 581, and 613
(SM + 3), or double mutant with one, two, or three additional
mutations (DM + 1, 2, or 3). (B) Distribution of mutations at codons
436, 581 and 613 in the baseline (study period 1) and follow-up
(study period 2) studies among isolates that are A437G/K540E
double mutant with one additional mutation. (C) Distribution of
mutations at codons 436, 581 and 613 in the follow-up study
among isolates that are A437G/K540E double mutant with two
additional mutations.
Spalding et al. Malaria Journal 2010, 9:338
http://www.malariajournal.com/content/9/1/338
Page 5 of 10two additional mutations, S436A/F and A581G most
commonly occurred together (Figure 3C).
In addition to evaluating changes in parasite genotypes
associated with drug resistance, in vitro IC50 values for
the common antifolates pyrimethamine, proguanil,
chlorcycloguanil, and dapsone were determined for
between 27 and 43 isolates from the follow-up study
(Table 1). The geometric mean IC50 of pyrimethamine
was 171.0 ng/ml and the geometric mean IC50 of sul-
phadoxine was 9.3 μg/ml.
To evaluate whether changes in quinoline resistance
occurred after SP replaced chloroquine as the first-line
anti-malarial, the prevalence of mutations in the genes
pfcrt and pfmdr1 were compared between the baseline
and follow-up studies. Mutations at pfcrt codon 76 and
at pfmdr1 codons 86, 184, 1034, 1042, and 1246 were
successfully analysed in 36 to 40 out of 40 samples from
the 1999-2000 study period and 243 to 247 out of 250
samples from the follow-up period (with the exception
of pfmdr1 codon 1246, for which 90 samples were geno-
typed). The prevalence of the pfcrt mutation K76T in
patient isolates increased between the study groups
from 82.1% to 97.1% (p = 0.001) (Figure 4). In the
pfmdr1 gene, significant changes in mutation prevalence
were observed at codons 86, 1034, and 1246. The
prevalence of the N86Y mutation increased from 43.6%
to 75.7% (p < 0.001), while at codons 1034 and 1246
mutation prevalence decreased from 100% to 6.1% (p <
0.001) and 31.5% to 4.4% (p < 0.001), respectively. The
mutation prevalence at codon 184 remained at 100% for
both the baseline and follow-up studies, and the preva-
lence of mutant codon 1042 was similar between the
baseline and follow-up studies (90.0% and 84.2%, respec-
tively; p = 0.475) (Figure 4).
The prevalence of wild-type pfcrt 76 has been increas-
ing in coastal Kenya [45] and in Tanzania [46]; there-
fore, it was important to evaluate whether Kisumu
isolates deviated from this trend due to an increase in
the frequency of the K76T allele or as a consequence of
the higher prevalence of polyclonal infections in the fol-
low-up study compared to the baseline study. The fre-
quency of the K76T allele in the baseline and follow-up
studies was estimated using the method of Hill and
Babiker [37]. The frequency of K76T was estimated to
be 77.8% (63.7%-88.5%) in the baseline study and 85.0%
(81.8%-87.9%) in the follow-up study.
IC50 values for 54 to 62 samples from the follow-up
study were obtained for CQ, mefloquine, quinine, and
amodiaquine (AQ) (Table 2). Geometric mean IC50
values for CQ, mefloquine, quinine, and AQ were 15.3,
12.0, 47.7, and 7.4 ng/ml, respectively. The prevalence of
in vitro resistance to CQ, mefloquine, and quinine was
also determined. The CQ resistance level is of particular
interest because the cutoff of 100 nM for resistant para-
sites was associated with in vivo treatment failure in
Cameroon [39], in contrast to other resistance cut-offs
that were determined statistically. In vitro resistance to
CQ was observed in 15% of the isolates; quinine in vitro
resistance was 1.6%, with 4.9% showing intermediate
levels of susceptibility; and 51.6% of isolates were resis-
tant to mefloquine.
Discussion
The first-line anti-malarial treatment regimen for
uncomplicated malaria in Kenya changed from CQ to
SP in 1998 and from SP to AL in 2004. In both
instances, the change was necessitated by widespread
treatment failure. The prevalence of SP and chloroquine
Table 1 In vitro geometric mean IC50 data for antifolates
in the follow-up study
Drug N Mean IC50
(ng/ml)
Range
(ng/ml)
Percent resistant
pyrimethamine 43 171 21-2028 16.3 (53.5)
a
chlorcycloguanil 41 2 0.5-11
proguanil 41 929 129-3376
sulphadoxine 41 9310 890-48,153 51.2
dapsone 27 648 16-129 14.8
a percent resistant using the intermediate level of susceptibility of 500 nM
(124.5 ng/ml) as the cutoff
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Figure 4 Prevalence of patient isolates with mutations in pfcrt
and pfmdr1 from the baseline study (study period 1) and
follow-up study (study period 2).
Table 2 In vitro geometric mean IC50 data for quinolines
in the follow-up study
Drug N Mean IC50
(ng/ml)
Range
(ng/ml)
Percent resistant
chloroquine 60 15.3 3-110 15
mefloquine 62 12.0 1-48 51.6
quinine 61 47.7 14-313 1.6 (4.9)
a
amodiaquine 54 7.4 3-24 0
a percent resistant using the intermediate level of susceptibility of 500 nM
(162.2 ng/ml) as the cutoff
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was compared between the period just after SP imple-
mentation (1999-2000) and a period five to seven years
later (2003-2005) in patients with febrile illness present-
ing to outpatient clinics in Kisumu, Kenya. Malaria in
Kisumu and in other areas surrounding Lake Victoria is
endemic. For the 12 months ending in June 2004, the
entomological inoculation rate in Kisumu district was
31.1 infective bites per person per year [47], and in the
time period 2003-2006, the median P. falciparum para-
site rate for children 2 to 10 years of age (PfPR2-10)w a s
71% in Kisumu [48]. Despite changes in government
anti-malarial policy, as late as 2010 SP was used to treat
malaria in 37% of households surveyed in Kisumu, com-
pared to 32% that used ACT [4].
The prevalences of pfdhfr codons N51I, C59R, and
S108N were near saturation in the baseline study [34]
and remained relatively stable between the baseline and
follow-up studies. In contrast, the prevalence of muta-
tions at all five pfdhps codons analysed increased drama-
tically over the same period. It thus appears that a
significant proportion of isolates carried pfdhfr muta-
tions prior to 1998, and use of SP as the first-line anti-
malarial in Kenya resulted in the development of highly
mutant pfdhps. Pre-existing mutations in pfdhfr may
have derived from a combination of two sources: the
u s eo fS Pa sas e c o n d - l i n ea n t i - m a l a r i a li nK e n y ap r i o r
to 1998 and the ongoing treatment of persons with
HIV/AIDS with co-trimoxazole, a bacterial DHFR/DHPS
inhibitor used to treat respiratory tract infections and
prevent opportunistic infections. Co-trimoxazole shows
cross-resistance with pyrimethamine and sulphadoxine
in in vitro P. falciparum culture [49,50] and may play a
role in the development of mutations in pfdhfr and
pfdhps.
One goal of this study was to determine whether the
prevalence of the clinically relevant pfdhfr/pfdhps quin-
tuple mutant, which is associated with SP treatment fail-
u r ei nA f r i c a[ 1 3 , 5 1 ] ,c h a n g e dd u r i n gt h ec o u r s eo fS P
use as the first-line anti-malarial in Kenya. Between the
baseline and follow-up studies, the prevalence of the
quintuple mutant doubled to 53.5% and may be even
higher. Due to absence of MOI data in these studies,
pfdhfr/pfdhps haplotypes were deduced according to the
method described by Kublin and colleagues [13].
Because this method conservatively classifies isolates
t h a ta r ep u r em u t a n ta to n epfdhfr allele and mixed at
two other pfdhfr alleles as double mutant, the preva-
lence of the pfdhfr triple mutant may be systematically
underestimated in populations where mixed infections
are common. In the follow-up study, many more isolates
had mixed pfdhfr genotypes than at baseline, and the
prevalence of the pfdhfr triple mutant decreased
between the baseline and follow-up studies. This
observation contrasts with other findings showing that
the population of SP-resistant parasites expanded over
this period, and may be explained by more severe sys-
tematic underestimation in the follow-up study com-
pared to the baseline. Thus, the prevalence of the pfdhfr
triple mutant and the pfdhfr/pfdhps quintuple mutant in
the follow-up study may actually be higher than esti-
mated here.
Although the prevalence of the pfdhfr triple mutant
appeared to decrease over time, increases in the preva-
lence of the pfdhps A437G/K540E double mutant led to
ar i s ei nt h epfdhfr/pfdhps quintuple mutant prevalence.
The very high prevalence of mutant codons 437 and 540
is consistent with other reports that these mutations are
common in western Kenya [19,52]. Notably, the data
presented here show that SP use in Kenya was not just
associated with the expansion of A437G and K540E, but
also the progressive accumulation of mutations in
pfdhps at codons 436, 581, and 613. This process
appears to be rapid, as demonstrated by the emergence
and spread of the A581G and A613S/T mutations in the
short time between the baseline and follow-up studies.
Mutations at pfdhps codons 436, 581, and 613 are
associated with increased levels of in vitro resistance
when they occur with the A437G mutation [20,43].
Among isolates in the follow-up study, over half had the
mutations S436A/F, A581G, and A613S/T in addition to
the A437G/K540E single or double mutant; A437G was
present in either mixed or pure form in all single
mutant isolates. Thus, at follow-up the majority of iso-
lates had parasite genotypes associated with extremely
high in vitro sulphadoxine resistance. Although the
effect of these mutations in vivo is not well-studied,
under SP selection, parasites containing the quintuple
mutant and A581G have been found to have a selective
advantage in vivo over quintuple mutant parasites [53].
This selective advantage is reflected in the swift develop-
ment and expansion of pfdhps mutations between the
baseline and follow-up studies.
This is the first study to report the presence of the
A581G mutation in Kenya. Although relatively rare in
sub-Saharan Africa, this mutation has been documented
in the neighboring countries of Uganda and Tanzania
[19]. In the background of mutant pfdhfr in Tanzania, a
similar increase in the prevalence of A437G and K540E
accompanied by the emergence and rapid spread of
A581G was observed over the six year period following
SP implementation [46]. Notably, in this and other East
African studies that reported the presence of A581G, all
or most samples were wild-type at codon 613 [46,53,54].
This contrasts sharply with the findings reported here,
where mutant codon 613 was present in over half of
patient isolates in the follow-up study. It thus appears
that the mutation A581G is becoming increasingly
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hotspot for the mutation A613S/T.
Although progressive mutations in pfdhps were observed,
the pfdhfr mutation I164L, which is associated with high
levels of chlorcycloguanil and pyrimethamine resistance in
South America and South East Asia, was absent from iso-
lates in both study periods. This mutation was detected in
isolates from Kisumu in 2002 [17], prior to the start of the
follow-up study, and in western Kenya in 2004 [18]. The
absence of the I164L mutation in isolates from the follow-
up study, conducted from 2003-2005, indicates that
parasites harboring this mutation in 2002 did not become
widespread in Kisumu. Taken together, these findings are
consistent with evidence that the I164L mutation is rare in
sub-Saharan Africa, outside local hotspots in south-west
Uganda and Rwanda [16,19,55].
The change from CQ to SP as the first-line anti-malar-
ial in 1998 was expected to decrease CQ use in Kenya,
possibly leading to restoration of CQ sensitive parasites.
In Malawi, discontinuing the use of CQ led to the rever-
sion of codon 76 to wild-type over a seven year period,
and CQ sensitivity in vivo was restored after 12 years
[32,33]. Trends of increasing prevalence of wild-type
codon 76 have recently been reported in other areas of
East Africa. In Tanzania, the prevalence of wild-type pfcrt
codon 76 increased over a six year period after anti-
malarial policy replaced CQ with SP [46]. Surveillance in
coastal Kenya from 1993-2006 showed that the wild-type
codon 76 prevalence also increased, although at a slower
rate than in Malawi [45]. Therefore, it was surprising to
observe a statistically significant increase in the preva-
lence of isolates containing pfcrt K76T from 82% to 97%,
as well as a significant increase in the prevalence of
pfmdr1 N86Y, also associated with chloroquine resis-
tance, from 44% to 76%. To analyse whether the apparent
increase in the prevalence of mutant codon 76 arose from
the higher prevalence of polyclonal infections observed in
the follow-up study, the method of Hill and Babiker was
used to estimate the frequency of the K76T allele. Even
accounting for polyclonal infections, there was an appar-
ent although not statistically significant increase in the
frequency of K76T. Thus, the K76T mutation does not
appear to be abating in Kisumu, as it is in coastal Kenya
and in other areas in East Africa.
The persistence of the pfcrt K76T mutation in isolates
from a high transmission setting such as Kisumu indi-
cates that selection for the mutant codon is ongoing. The
pfcrt K76T mutation is associated with amodiaquine as
well as chloroquine treatment failure [56]. Although AQ
was officially the second-line therapy used in Kenya dur-
ing the study period, it was available at 95% of drug retail
outlets, whereas SP was available at only 29% of outlets
[57]. By comparison, CQ was stocked by 15% of drug
retail outlets [57]. It thus appears that widespread use of
AQ in the private sector may be high enough to exert
selective pressure on the parasite population.
Specific pfmdr1 genotypes have been linked to altered
susceptibility to artemisinin, a component of the current
first-line anti-malarial therapy AL. In vitro, the allele
combination S1034C/N1042D/D1246Y is associated
with increased artemisinin susceptibility [28], and in
vivo, treatment with AL selects for the N86, Y184F, and
D1246 alleles [29,30]. In this study, the prevalence of
alleles associated with artemisinin sensitivity (S1034C
and D1246Y) decreased significantly; however, this
decline is not likely due to selective pressure induced by
AL as completion of the follow-up study predated wide-
spread use of AL. Whether the prevalence of pfmdr1
mutations continues to change under increasing AL
pressure will be of interest.
Conclusions
During the period in which SP was used as the first-line
anti-malarial in Kenya, the prevalence of clinically relevant
molecular markers of SP and CQ resistance increased in
Kisumu, a city located on the shore of Lake Victoria in a
malaria endemic region. Mutations at pfdhps codons 581
and 613, which have not previously been observed in
Kenya, became highly prevalent during this period. In light
of these highly SP-resistant genotypes and reports that SP
remains widely used in Kenya [4], it is important to dis-
courage use of SP to treat symptomatic malaria, parti-
cularly for populations that are not semi-immune.
Furthermore, whether the pfdhfr/pfdhps quintuple mutant
combined with the pfdhps mutations S436A/F, A581G,
and A613S/T adversely impacts the efficacy of IPTp and
IPTi should be evaluated. The continued rise in the preva-
lence of mutations associated with CQ resistance indicates
that continued drug pressure, either from CQ or amodia-
quine use, is preventing restoration of CQ-susceptible
parasites in Kisumu. That these findings contrast with a
study covering the same period in coastal Kenya [45] high-
lights the importance of surveillance and the heterogeneity
in drug resistance that may occur within a country.
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Additional file 1: Classification of pfdhfr and pfdhps genotypes.
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pfdhfr/pfdhps haplotype classifications.
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